Sonova H Ag (0QPY)
London Exchange · UK · prices in GBP · close of 23 Oct 2026
Key indicators
| Last close | GBP 283.80 |
|---|---|
| 52-week range | 163.20 – 283.80 |
| Return, 1 month / 3 months | +18.4% / +35.7% |
| Return, 1 year / 3 years | +24.3% / +33.7% |
| Trend | Uptrend |
| RSI (14) | 85 |
| Volatility (1 year) | 28.0% |
| Worst drawdown (1 year) | -27.0% |
| Average daily value traded | 10.44M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sonova is a hearing care company based in Switzerland. It develops and makes hearing aids, which it sells through brands such as Phonak and Unitron, along with wireless accessories that connect the devices to phones, televisions and other audio sources. Through its cochlear implant business it offers implantable hearing solutions for people with severe hearing loss. Its customers are hearing care professionals, clinics and the people who use its products, served through a network of retail outlets and distributors in many countries.
Sonova H Ag trades under the code 0QPY on the London Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sonova H Ag (0QPY) trades on the London Exchange in UK. It last closed at GBP 283.80 on 23 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 114 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 24.3% and over the last three months it rose 35.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 94 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 34.3% | ||
| From 52-week high | 0.0% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 35.7% | ||
| 6-month return | 61.5% | ||
| 12-month return, skipping the last month | 5.0% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.0% | ||
| Liquidity | 74 · Strong | Trades actively. | |
| Average daily value traded | 10.44M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.0% |
|---|---|
| 1 month | +18.4% |
| 3 months | +35.7% |
| 6 months | +61.5% |
| 1 year | +24.3% |
| 3 years | +33.7% |
| 5 years | −24.1% |
Signals
| 50-day / 200-day average | 247.46 / 211.33 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 11.98 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Jun 2026 | GBX 0.0470 |
| 13 Jun 2025 | GBX 0.0440 |
| 13 Jun 2024 | GBX 0.0430 |
| 14 Jun 2023 | GBX 0.0460 |
| 17 Jun 2022 | GBX 0.0440 |
| 17 Jun 2021 | GBX 0.0320 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.